ASCO® 2023 Insights: "Phase III FIRE-4 Study - Influence of Baseline Liquid Biopsy Results in 1L Treatment Efficacy of FOLFIRI/Cetuximab in Pts With Tissue RAS-WT mCRC"

0 views
June 15, 2023
Comments 0
Login to view comments. Click here to Login